Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India

CONCLUSION: Rituximab is an effective immunomodulatory therapy in MuSK antibody-positive MG patients who are not responding to the standard treatment.

Source: Indian Journal of Pharmacology - March 10, 2020 Category: Drugs & Pharmacology Authors: Julie Sachdeva Karthik Vinay Mahesh Ritu Shree Gaurav Jain Aastha Takkar Kapila Tirulapati Padmavathi Shashikala Manoj Kumar Goyal Manish Modi Vivek Lal Source Type: research